Sabio Group Acquires makepositive, Expanding Focus on Customer Relationship Management
Sabio Group, a leading European full service CX provider, has acquired makepositive, a large UK-based independent Salesforce consulting partner. makepositive will strengthen Sabio’s ability to support customers with transformative cutting-edge CX technologies, particularly addressing the Human Service aspect of the CRM Customer Engagement Centre.
Founded in 2003, makepositive is a multi-award-winning Salesforce consulting partner, with circa 180 employees, offices in London and Manchester, and a development centre in India. makepositive has over 120 Salesforce-accredited consultants with 700+ Salesforce certifications amongst them, as well as its own dedicated managed services capability. The company has delivered Salesforce projects for leading organisations, including Allocate, Aston Martin, Fujifilm, Gamma, McCarthy & Stone, Sohonet, Visioncall and Wolseley.
“With AI and conversational technologies now handling many routine CX enquiries, contact centre advisors handle a greater proportion of complex customer interactions. This has introduced more complexity on the advisor desktop, increasing the need for assistive Human Service solutions that offer true real-time digital support for advisors,” said Sabio Group’s CEO, Jonathan Gale. “Salesforce is a driving force in this space as traditional Contact Centre technologies merge with the Customer Engagement Centre market. Acquiring makepositive and bringing its proven design, implementation and maintenance skills across multiple Salesforce clouds into Sabio Group is an important and timely move.”
“In Sabio Group we have found a new, exciting home and, with access to Sabio’s resources, we will be able to accelerate our mission to deliver digital transformations for our customers,” added makepositive’s CEO, Mark Richards. “There’s a great connection and cultural fit between the two organisations.”
“Sabio will be key to helping makepositive extend its footprint and take advantage of the growing demand for solutions that deliver exceptional customer and employee experiences,” said Matt Cooksley, makepositive’s COO. “For the past 10 years, our focus has been on becoming a leading independent Salesforce consulting partner in the UK. We are now looking forward to expanding that journey with Sabio as we increase the reach and depth of our customer offerings.”
Commenting on Sabio Group’s acquisition of makepositive, Leon Mangan, Salesforce’s Senior Vice President Alliances & Channels for EMEA & LATAM, said: “Salesforce is investing for growth in the UK, and our partner ecosystem is an essential driving force behind this. It’s great that makepositive, a leading UK Salesforce consulting partner, is taking its business forward to the next level as part of the Sabio Group. We look forward to their continued success in the dynamic CRM Customer Engagement Centre space.”
Notes:
Salesforce, and others are among the trademarks of salesforce.com, inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005029/en/
Contact information
Craig Pumfrey
Tel: +44(0)7887 824511
cpumfrey@sabio.co.uk
Cheryl Billson
Tel: +44(0)7791 720460
cheryl.billson@commacomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom